Clinical Implications of Natalizumab Fab-Arm Exchange in Multiple Sclerosis

08 May 20264 min read0 viewsJournal Feed

GIST

Natalizumab, a monoclonal antibody used to treat multiple sclerosis, can undergo Fab-arm exchange (FAE) with endogenous IgG4, resulting in a monovalent form with reduced avidity and presumed lower potency than the parental bivalent form. Levels of bivalent and monovalent natalizumab depend on the ratio of endogenous IgG4 to total natalizumab, which varies substantially between individuals.

The clinical relevance of natalizumab FAE remains unknown. This study investigated the potential clinical implications of bivalent and monovalent natalizumab levels regarding progressive multifocal leukoencephalopathy (PML), extended interval dosing (EID) and wearing-off symptoms, using multiple cohorts of natalizumab-treated patients.

Seven natalizumab-associated PML cases were each matched to two controls. Contrary to the hypothesis that higher bivalent levels might increase PML risk, cases showed a trend toward lower bivalent natalizumab levels, although definite conclusions were limited by small sample size.

In patients receiving EID, both total and bivalent natalizumab levels decreased compared to standard interval dosing, with a greater median individual decrease in bivalent natalizumab than in total natalizumab (94% versus 78%).

Clinical Editorial

Study scope and design

The investigation centers on the exchange between natalizumab and endogenous IgG4, producing monovalent forms with lower avidity relative to the parental bivalent molecule.
The proportion of bivalent versus monovalent natalizumab varies with each patient’s endogenous IgG4 to total natalizumab ratio, leading to substantial interindividual differences.
The clinical relevance of Fab-arm exchange in natalizumab-treated MS patients remains uncertain.

PML signal and case–control observations

In a matched case–control framework focusing on natalizumab-associated progressive multifocal leukoencephalopathy (PML), seven PML cases were each paired with two controls.
The working hypothesis that higher bivalent natalizumab levels might elevate PML risk was not supported; observed cases tended to have lower bivalent levels, though the small sample size limits definitive conclusions.

Dosing strategy and pharmacokinetic implications

Extended interval dosing (EID) was associated with reductions in both total natalizumab and bivalent natalizumab levels compared with standard interval dosing.
The decline was more pronounced for the bivalent fraction, with a median decrease of 94% versus 78% for total natalizumab.
In over half of patients on EID, bivalent natalizumab fell below the quantification threshold (<0.1 µg/mL), indicating substantial diminishment of the bivalent pool.

Wearing-off symptoms and potential associations

Patients reporting wearing-off symptoms during natalizumab therapy exhibited lower bivalent natalizumab levels.
Validation of this association requires larger, prospective cohorts to establish robustness.